ApoGen fetches $11 mln Series A
Seattle-based ApoGen Biotechnologies Inc, a cancer drug developer, has raised $11 million in Series A financing. The investors included M Ventures. In conjunction with the funding, Dr. Keno Gutierrez, an investment director at M Ventures, has joined ApoGen's board of directors.
23 August 2018•1 min read
